Yale Podnos - 08 Jun 2026 Form 4 Insider Report for Oncology Institute, Inc. (TOI)

Reporting relationship: Chief Medical Officer
Issuer ticker: TOI
Reported as of: 08 Jun 2026
Net transaction value: -$126,094
SEC form: 4
Accepted by SEC: 09 Jun 2026, 19:06:28 UTC
Prior SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Yale Podnos

Key filing fact

Yale Podnos filed Form 4 for Oncology Institute, Inc. (TOI) on 09 Jun 2026.

Key facts

This page summarizes Yale Podnos's Form 4 filing for Oncology Institute, Inc. (TOI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Jun 2026, 19:06.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: -$126,094.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001891104 Primary reporting owner

Podnos Yale

Relationship: Chief Medical Officer
Address: C/O THE ONCOLOGY INSTITUTE INC., 18000 STUDEBAKER RD, SUITE 800, CERRITOS
Signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Yale Podnos
Signature date: 09 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TOI transaction

Common Stock

Sale

Transaction value: $126,094
Shares: -23,451
Change %: -8.3%
Price: $5.38
Shares after: 259,527
Date: 08 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Price is the volume weighted average selling price of all sales on behalf of the Reporting Person on June 8, 2028 within a one-dollar range. Actual prices ranged from $5.35 to $5.42. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

Footnote F2

Sales were made on behalf of the Reporting Person pursuant to the Rule 10b5-1(c) plan that was adopted on 08/26/2025.